Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Osteochondroma 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Lung Neoplasms 1Hematologic Neoplasms 1Giant Cell Tumors 1Fibrosis 1Endometrial Hyperplasia 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Specimen Handling 482pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 241Paclitaxel 226Gemcitabine 224Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 166Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 143Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sampling Studies × 1 year × Clear all
NCT05463796 2025-08-07

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

Recruiting
5,000 enrolled
GastrointestinalGynecologicOther hematologic neoplasmThoracic

Barrett Esophagus, Carcinoma in Situ, Endometrial Hyperplasia, Fibrosis, Giant Cell Tumors, Lung Neoplasms, Osteochondroma, Carcinoma, Lobular, Nevus, Epithelioid and Spindle Cell, Hematologic Neoplasms, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡